Imatinib mesylate-induced pseudoporphyria in two children
Caroline Mahon1, Diana Purvis, Stephen Laughton
1Department of Paediatric Dermatology, Starship Children's Health, Auckland, New Zealand.
Pediatric Dermatology
|June 13, 2014
Summary
Imatinib mesylate, a cancer drug, can cause pseudoporphyria, a rare skin condition. This study highlights two pediatric cases, urging physicians to monitor for this adverse effect in children treated with imatinib.
Area of Science:
- Oncology
- Dermatology
- Pediatrics
Background:
- Imatinib mesylate is a tyrosine kinase inhibitor used to treat various cancers.
- Adverse cutaneous reactions are common with imatinib therapy.
- Pseudoporphyria is an infrequently reported side effect in adults on imatinib.
Observation:
- This report details two pediatric cases of pseudoporphyria.
- Both children were undergoing imatinib therapy for hematologic malignancies.
- The pseudoporphyria was directly linked to imatinib treatment.
Findings:
- Pseudoporphyria can occur in children treated with imatinib.
- This adverse reaction is associated with imatinib's mechanism of action.
- The incidence of pseudoporphyria in pediatric patients is not well-documented.
Implications:
- Physicians should be vigilant for pseudoporphyria in children receiving imatinib.
- Early recognition and management of this side effect are crucial.
- Increased awareness may improve patient outcomes and safety in pediatric oncology.
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
93
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
93
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
01:16Drug toxicity: Idiosyncratic Reactions
219
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
219